TAOX vs HIVE

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 09, 2026

TAOX

50.3
AI Score
VS
HIVE Wins

HIVE

61.6
AI Score

Investment Advisor Scores

TAOX

50score
Recommendation
HOLD

HIVE

62score
Recommendation
BUY

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric TAOX HIVE Winner
Revenue 388,774 225.97M HIVE
Net Income 4.25M -72.11M TAOX
Net Margin 1094.3% -31.9% TAOX
ROE 18.3% -12.9% TAOX
ROA 13.7% -11.6% TAOX
Total Assets 31.05M 624.00M HIVE
Cash 3.65M 14.07M HIVE
Current Ratio 27.40 1.74 TAOX

Relative Price Performance (Last 90 Days)

TAOX 1M: -8.7% · 3M: -45.3% HIVE 1M: -15.5% · 3M: -1.0%

Current Technical Phase

TAOX

Markdown
Sell / avoid

Price below a falling SMA50 (slope -16.4%), weak momentum, RSI 44

RSI (14): 44.2 · Price: $3.37

HIVE

Markdown
Sell / avoid

Price below a falling SMA50 (slope -1.8%), weak momentum, RSI 43

RSI (14): 43.4 · Price: $2.84

Fundamentals Snapshot

Metric TAOX HIVE
Market Cap
Forward P/E 0.0 -5.6
Trailing P/E
Revenue (TTM)
Revenue Growth 0.0% 1.3%
Gross Margin 1.0% 0.4%
Operating Margin -3.4% -0.8%
EPS -8.29 -0.64
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, HIVE is currently the stronger investment candidate, winning 3 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.